Physician profile
George Burnett
NPI 1679559934
$2,806.09
in general payments reported to CMS, 2019-2025
31 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $237 · 2021: $312 · 2022: $294 · 2023: $376 · 2024: $515 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $455.57 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.64 | 2019-2025 | Jardiance |
| Pfizer INC. | $257.58 | 2019-2023 | |
| Amgen INC. | $254.34 | 2019-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $159.83 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Vanda Pharmaceuticals INC. | $145.17 | 2023-2024 | Hetlioz |
| Amarin Pharma, INC. | $142.79 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $128.85 | 2020-2024 | Eliquis |
| Lilly USA, LLC | $103.51 | 2023-2025 | Jardiance, Emgality, Trulicity |
| Novartis Pharmaceuticals Corporation | $89.44 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $82.04 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.10 | 2019 | |
| Phathom Pharmaceuticals, INC. | $60.37 | 2025 | Voquezna |
| Allergan, INC. | $60.24 | 2019-2020 | |
| Exact Sciences Corporation | $54.36 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $49.79 | 2023-2024 | Rexulti |
| Corcept Therapeutics | $46.94 | 2025 | Korlym |
| Abbvie INC. | $46.40 | 2020-2025 | |
| Esperion Therapeutics, INC. | $43.76 | 2021-2024 | Nexletol |
| Abbott Laboratories | $41.45 | 2024-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $31.96 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $30.82 | 2022 | |
| Amneal Pharmaceuticals LLC | $27.91 | 2025 | Unithroid |
| Teva Pharmaceuticals USA, INC. | $27.36 | 2019 | |
| Astellas Pharma US INC | $24.78 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $21.23 | 2024 | Arexvy, Trelegy Ellipta |
| Arbor Pharmaceuticals, INC. | $16.56 | 2019 | |
| Alk-Abello, INC | $15.17 | 2025 | Odactra, Ragwitek, Grastek |
| Astrazeneca Pharmaceuticals LP | $15.04 | 2022 | |
| Cequr Corporation | $10.89 | 2024 | Cequr Simplicity |
| Takeda Pharmaceuticals U.S.A., INC. | $10.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Burnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.